MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Merus NV

Cerrado

SectorSalud

94.56 -0.3

Resumen

Variación precio

24h

Actual

Mínimo

94.56

Máximo

95

Métricas clave

By Trading Economics

Ingresos

-62M

-158M

Ventas

-19M

7.5M

Margen de beneficio

-2,110.989

Empleados

260

EBITDA

-595K

-93M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

+2.97% upside

Dividendos

By Dow Jones

Próximas Ganancias

30 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

2.2B

7.2B

Apertura anterior

94.86

Cierre anterior

94.56

Noticias sobre sentimiento de mercado

By Acuity

29%

71%

63 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Merus NV Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

19 oct 2025, 20:00 UTC

Adquisiciones, fusiones, absorciones

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

19 oct 2025, 23:44 UTC

Charlas de Mercado

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

19 oct 2025, 23:37 UTC

Charlas de Mercado

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

19 oct 2025, 23:36 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

19 oct 2025, 23:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 oct 2025, 23:09 UTC

Charlas de Mercado

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

19 oct 2025, 22:41 UTC

Adquisiciones, fusiones, absorciones

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

19 oct 2025, 22:30 UTC

Ganancias

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

19 oct 2025, 22:18 UTC

Charlas de Mercado

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

19 oct 2025, 21:50 UTC

Charlas de Mercado

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

19 oct 2025, 21:15 UTC

Charlas de Mercado

Investors Need to Change Narrative Toward Scales -- Market Talk

19 oct 2025, 19:34 UTC

Adquisiciones, fusiones, absorciones

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

19 oct 2025, 19:34 UTC

Adquisiciones, fusiones, absorciones

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

19 oct 2025, 19:33 UTC

Adquisiciones, fusiones, absorciones

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

19 oct 2025, 19:32 UTC

Adquisiciones, fusiones, absorciones

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

19 oct 2025, 19:32 UTC

Adquisiciones, fusiones, absorciones

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

19 oct 2025, 19:31 UTC

Adquisiciones, fusiones, absorciones

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

19 oct 2025, 19:31 UTC

Adquisiciones, fusiones, absorciones

Infratil to Acquire Additional 4.92% Stake in Contact Energy

19 oct 2025, 16:29 UTC

Ganancias

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

19 oct 2025, 11:14 UTC

Ganancias

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

19 oct 2025, 11:14 UTC

Ganancias

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

19 oct 2025, 11:14 UTC

Ganancias

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

18 oct 2025, 13:30 UTC

Adquisiciones, fusiones, absorciones

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 oct 2025, 13:30 UTC

Adquisiciones, fusiones, absorciones

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 oct 2025, 13:30 UTC

Adquisiciones, fusiones, absorciones

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 oct 2025, 13:30 UTC

Adquisiciones, fusiones, absorciones

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 oct 2025, 08:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

17 oct 2025, 23:25 UTC

Adquisiciones, fusiones, absorciones

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 oct 2025, 22:15 UTC

Charlas de Mercado

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 oct 2025, 21:15 UTC

Charlas de Mercado

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Comparación entre iguales

Cambio de precio

Merus NV Esperado

Precio Objetivo

By TipRanks

2.97% repunte

Estimación a 12 meses

Media 97.71 USD  2.97%

Máximo 112 USD

Mínimo 92 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merus NV Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

17 ratings

3

Comprar

14

Mantener

0

Vender

Puntuación técnica

By Trading Central

39.445 / 44.36Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

63 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
help-icon Live chat